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Abstract: The macrocyclic antibiotic mangrolide A has been reported to exhibit potent activity against a number of clinically important Gram-
negative pathogens. Herein we report the first enantioselective total synthesis of mangrolide A and derivatives. Salient features of our synthesis 
include a highly convergent macrocycle preparation, stereoselective synthesis of the disaccharide moiety and two b-selective glycosylations. 
The synthesis of mangrolide A and its analogues enabled the re-examination of its activity against bacterial pathogens, and only minimal 
activity was observed.  
Antimicrobial resistance (AMR) is an increasing serious threat to global public health and the annual loss of life is expected to reach 
10 million deaths by 2050 with an economic cost of $100 trillion.[1] Effectively addressing AMR requires a multifaceted approach that 
facilitates sustainable and appropriate use of existing antimicrobials, but also calls for new antibiotics. The development of lead 
structures with new molecular scaffolds and mechanisms of action thus constitutes an important goal. Particularly, while several 
antibiotics against infections caused by Gram-negative bacteria are in clinical development today, many constitute modifications of 
existing antibiotic classes, as the discovery of novel antibiotics that i) can penetrate the outer and inner membrane, and ii) are not 
subject to extensive efflux remains very challenging.  
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Mangrolide A (1) was isolated from the SNA18 strain of Actinoalloteichus sp. following phenotypic screening against Burkholderia 
cepacia (Figure 1).[2] A preliminary biological study revealed that this natural product is active against Gram-negative bacteria 
including Acinetobacter baumannii (MIC = 0.25 µg/mL) and Pseudomonas aeruginosa (MIC = 1.0 µg/mL). This antibacterial activity 
has been suggested to involve interaction with the 30S subunit of the ribosome leading to mistranslation.[4] Interestingly, fidaxomicin 
(2), a clinically approved antibiotic against Gram-positive bacteria, shares an almost identical 18-membered macrocyclic scaffold with 
mangrolide (1), while the carbohydrate and resorcylate moieties are replaced. Most surprisingly, the biological activity and target 
protein completely changes with these structural alterations from activity against Gram-positive bacteria by RNA polymerase 
inhibition (for 2) to activity against Gram-negative species by ribosome inhibition (for 1).[4, 5] This change of biological properties 
when switching the molecular decoration of a macrocyclic antibiotic is highly unusual and warrants further studies.  
The structure of mangrolide A (1) is characterized by a highly unsaturated 18-membered macrocycle decorated with the unusual 
carbohydrates, D-2,4-dimethyl quinovose and D-mycaminose,[3] both connected via b-glycosidic bonds. Synthetic challenges of 
mangrolide A (1) include (1) the stereoselective construction of the macrocyclic macrocyclic core,[6] (2) the regioselective 
functionalization as well as the stereoselective synthesis of both carbohydrates and, most importantly, (3) the two b-selective 
glycosylation reactions. Despite notable advances in carbohydrate chemistry, methods for the construction of b glycosidic bonds of 
N-alkylamino sugars are rare,[7] although some successful total syntheses of compounds containing this motif have been published.[8] 
In addition, the b-selective glycosylation at the sterically demanding C11 hydroxy group was expected to be challenging based on our 
earlier experiences in the fidaxomicin synthesis.[6b] To date, one synthetic study towards mangrolide A (1) has been documented in a 
patent by De Brabander and co-workers.[4] However, to the best of our knowledge, no total synthesis nor detailed antibiotic testing has 
been reported, presumably due to the challenging glycosylation chemistry and the complex macrocyclic features.[9] In this 
communication, we report on the first total synthesis of mangrolide A (1) and on the biological evaluation against bacterial pathogens 
as well as in vitro mechanism of action studies. 
Our retrosynthetic analysis of mangrolide A (1) is illustrated in Scheme 1. Mangrolide A was disconnected at the b-glycosidic bond 
expecting that the glycosylation with azidodisaccharide 3 and the protected macrocycle 4 would proceed with the aid of the 
neighbouring acyl group.[10] We envisaged that the strategic late-stage N-dimethylation of the azide intermediate not only would 
facilitate smooth glycosidation, but also would provide a key azide analogue to investigate the biological importance of the 
dimethylamino group (vide infra). The advanced carbohydrate intermediate 3 was expected to be synthesized from D-quinovose 5 and 
D-mycaminose precursor 6 by b-selective glycosylation with the aid of the nitrile effect.[11] Quinovose 5 would be obtained from 
glycoside 7 and the D-mycaminose precursor 6 from 2-acetylfuran (8) by employing the protocol developed by O'Doherty.[12] The 
macrocyclic part 4 was proposed to be synthesized by ring closing metathesis, Suzuki coupling and Yamaguchi esterification as key 
steps.[6a, b]  
 
Scheme 1. Retrosynthetic analysis. LG = leaving group, PMB = 4-methoxybenzyl, TBS= tert-butyldimethylsilyl, RCM = ring-closing metathesis. 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Synthesis of the quinovose domain 14. Reagents and conditions: a) DIBAL, PhMe, –20 to 10 °C; b) PPh3, I2, imid., CH2Cl2, reflux, 76% (2 steps); c) 
Pd(OH)2, H2 (balloon), DIPEA, MeOH; d) Pd/C, H2 (balloon), MeOH, 90% (2 steps), e) MeOTf, 2,6-(t-Bu)2Py, DCE (1 M), 88%; f) H2SO4 (5 mol%), Ac2O, 
0 °C; K2CO3, MeOH, quant.; g) CF3C(=NPh)Cl, K2CO3, acetone, 0 °C to rt, 82%. DIBAL = diisobutylaluminium hydride, imid. = imidazole, DIPEA = N,N-
diisopropylethylamine, OTf = trifluoromethanesulfonate, DCE = 1,2-dichloroethane, Py = pyridine. 
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The synthesis of the quinovose domain began by installing the C2´´ methyl group and C3´´ TBS ether onto methyl D-glucopyranoside 
(7) (Scheme 2).[13] Notably, the sequence was completely selective to give 9 in 73% over 3 steps including a single chromatographic 
purification. Selective cleavage of the benzylidene acetal at the C6´´ position[14] followed by iodination[15] gave iodide 10, which was 
reductively dehalogenated and deprotected to provide quinovose 11. Next, alcohol 11 was treated with a strong methylating reagent 
MeOTf[16] to provide methyl ether 12. Retention of the TBS group at the C3´´ hydroxy group was confirmed by transformation to the 
corresponding acetate (TBAF; Ac2O). Acetal exchange under acidic conditions and hydrolysis of the intermediate acetate followed by 
the imidate addition reaction afforded acetimidate 14, suitable for glycosylation.  
Next, we set out to investigate the b-selective glycosylation with separately synthesized epoxy alcohol 6[12, 17] (Scheme 3). Various 
glycosyl donors and activation conditions were examined without success (glycosylfluoride,[18a] thioglycoside,[18b] 
phosphoramidate,[18c] phosphite ester,[18d] trichloroacetimidate[18e,f]). Extensive experimentation revealed that the combination of 
trifluorophenylacetimidate 14[19] and Ph3CB(C6F5)4[20] in a n-PrCN/ CH2Cl2 mixture resulted in disaccharide b-15 in 81% yield with 
4.3 to 1 selectivity in favor of the b diastereoisomer. This ratio and yield are worth noting as the selectivity of nitrile assisted 
glycosylations are generally low in the presence of a silyl group, especially when the C4 hydroxy group of another sugar is employed 
as the acceptor.[6b] With careful control of temperature and stirring, this reaction was scaled to gram level. We speculate that the very 
weak tendency of the bulky tetrakis(pentafluorophenyl)borate anion towards coordination of the oxocarbenium cation[21] contributes 
to the preferential formation of the α-nitrile adduct, which is effectively attacked from the b side to form the desired glycosidic bond. 
To the best of our knowledge, this catalyst system is the first example of b-glycosylation using acetimidate donors, although the 
activation of glycosyl fluorides and thioglycosides are well studied by Mukaiyama and co-workers using the same catalyst.[18a, 22] Next, 
epoxide opening[17] of disaccharide 15 using an azide nucleophile was performed and the desired equatorial adduct 16 was isolated in 
80% yield after acetylation of the resultant C2´ alcohol. At this stage, the use of the acetate as a protecting group was essential for the 
separation of the two regioisomers. Deprotection of the PMB group and formation of the imidate afforded donor 17 as a mixture of 
anomers (α/β 1:1) in quantitative yield.  
 
 
Scheme 3. Synthesis of the azidodisaccharide donor 17. Reagents and conditions: a) 14 (1.2 eq), Ph3CB(C6F5)4 (5 mol%), MS 3Å, n-PrCN/CH2Cl2 = 
1:5, –95 to –40 °C, 4 h, β/α 4.3:1, 81% (β); b) NaN3, NH4Cl, EtOH, 80 °C; c) Ac2O, Et3N, DMAP, 80% (2 steps); d) DDQ, CH2Cl2, pH7 phosphate 
buffer, quant.; e) CF3C(=NPh)Cl, K2CO3, acetone, 0 °C to rt, quant. MS = molecular sieves, DMAP = 4-(dimethylamino)pyridine, DDQ = 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone. 
 
Having synthesized the azidodisaccharide donor 17, we set about the final assembly starting with macrocycle preparation (Scheme 4). 
Suzuki coupling[6b, c] of previously synthesized iodide 18[6a, f] and separately prepared boronate 19[23] provided the desired alcohol in 
excellent yield. This synthetic intermediate was then converted into the corresponding linear polyene 22 through Yamaguchi 
esterification with acid 20.[6a, f] A ring-closing metathesis reaction with second generation Grubbs catalyst and subsequent hydrolysis 
of the nitrobenzoate ester at C11 afforded alcohol 4 as a mixture of (E,E) and (E,Z) isomers. Fortunately, these stereoisomers could be 
successfully separated after the TMS protection, and the subsequent silyl deprotection gave access to the pure (E,E) isomer. Next, 
azide donor 17 was reacted with  macrolactone 4 using TBSOTf as an activator. To our surprise, the reaction proceeded smoothly to 
provide the desired b-isomer in 42% yield with complete selectivity. This yield was striking given that the glycosylation of such a 
hindered system could never be achieved on a related system in our previous fidaxomicin synthesis.[6b, 6f] The key to this success is 
attributed to higher stability[24] and less steric hindrance of the rationally designed glycosyl donor. In addition, the use of the azide 
donor was essential, as a model study using various glycosyl donors with the N,N-dimethylamino group and different activation 
conditions never resulted in the desired product in acceptable yield. 
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Scheme 4. Total synthesis of mangrolide A (1). Reagents and conditions: a) 19 (1.25 eq), Pd(PPh3)4 (10 mol%), TlOEt (1.5 eq), THF, H2O, 0 °C to rt, 30 min, 
quant.; b) 20 (2.5 eq), TCBC, Et3N, THF; DMAP, PhMe, 68%; c) Grubbs II (20 mol%), PhMe, 100 °C, 2 h, E, E/E, Z = 2.7:1; d) NaOMe, MeOH, Et2O, 2 h, 91% 
(2 steps); e) TMSCl, imid., CH2Cl2, 0 °C, 15 min, 53%; f) AcOH, MeOH, 5 h, quant.; g) 17 (1.5 eq), TBSOTf (15 mol%), CH2Cl2, rt, 15 min, 42%; h) NaOMe, 
MeOH, Et2O, 14 h; i) 3HF•NEt3, THF, 50 °C, 24 h, 80% (2 steps); j) TCEP, phosphate buffer, THF, MeOH, 2N NaOH, H2O, 2 days; 37% aq. CH2O, NaBH3CN, 
H2O, MeCN, 1 h, 25% (2 steps). Pin = pinacolato, THF = tetrahydrofuran, TCBC = 2,4,6-trichlorobenzoyl chloride, TMSCl = chlorotrimethylsilane. TBSOTf = 
tert-butyldimethylsilyl trifluoromethanesulfonate, TCEP = tris(2-carboxyethyl)phosphine hydrochloride. 
 
Next, the acetyl and TBS groups were cleaved to give tetraol 24. Finally, reduction of the azide group by TCEP followed by reductive 
amination and purification by reversed-phase HPLC afforded fully synthetic mangrolide (1). The NMR spectra of the formate adduct 
(2 equiv.) of the synthetic material 1 matched those reported for the natural product.[2, 4] 
With synthetic (+)-mangrolide A (1) and the derivative 24 in hand, we began testing against a panel of bacteria (see also the Supporting 
Information).[2, 4] As outlined in Table 1, while for natural 1 low micromolar activity had been reported,[2, 4] synthetic 1 did not show 
any activity against the reference isolates and clinical strains tested. There was no activity against a laboratory-generated mutant of E. 
coli with increased permeability ( rfaC) and decreased efflux ( tolC). The spectrum and the activity of fidaxomicin (2) was 
essentially as reported.[25] 
 
 
Table 1. Minimal inhibitory concentrations of mangrolide A and derivatives against 
Gram-positive and Gram-negative bacterial strains[a] 
compound S.a.[b] E.f.[c] C.d.[d] E.c.[e] E.c.[f] A.b.[g] P.a.[h] 
Mangrolide A >16 >16 >16 >16 >16 >16 >16 
24 >16 >16 >16 >16 >16 >16 >16 
Fidaxomicin 8 4 ≤0.06 >32 8 >32 >32 
[a] Bacterial isolates are from the Idorsia strain collection. Minimal inhibitory concentrations (MICs, in µg/ml) were determined by the broth micro-dilution 
method according to guidelines of the Clinical and Laboratory Standards Institute (CLSI).[26] [b] S.a.; Staphylococcus aureus ATCC 29213. [c] E.f.; 
Enterococcus faecalis ATCC 29212. [d] C.d.; Clostridium difficile ATCC 70057. [e] E.c.; Escherichia coli ATCC 25922. [f] E.c.; Escherichia coli 2085 (DrfaC 
DtolC). [g] A.b.; Acinetobacter baumannii A-1305. [h] P.a.; Pseudomonas aeruginosa ATCC 27853. 
As the bacterial strains used in the literature may be more susceptible than the ones described herein, we decided to perform an enzyme 
assay to investigate the proposed mechanism of inhibition and in vitro potency (Table 2). Mangrolide A (1) and derivatives were tested 
in a coupled E. coli S30 in vitro transcription/translation (IVTT) assay. Mangrolide A (1) inhibited the translation with equal potency 
also when a phage promoter was used, just as the erythromycin positive control did, but in contrast to fidaxomicin (2), where the 
inhibition transcription was dependent on a bacterial promoter. We therefore concluded that mangrolide A (1) inhibits protein 
translation as previously described. However, the IC50 value was 50 – 100-fold higher than the ones determined for erythromycin or 
fidaxomicin, which may explain the absence of antibacterial activity. Comparing the in vitro activity of 1 to 24 it also became apparent 
that the N,N-dimethylamino group plays a key role for biological activity. The reason for the discrepancy of the observed to the 
reported biological activity for compound 1 remains unclear, contamination by a highly active minor constituent in the natural product 
would present an explanation.[27] 
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Table 2. Activities in E. coli cell-free transcription and translation assay (IVTT)[a] 
compound E. coli promoter SP6 promoter 
 
 
Mangrolide A 6.45 8.31  
24 80.8 ND  
Erythromycin 0.09 0.05  
Fidaxomicin 0.04 76.6  
[a] Assay as described[28] with the following modifications to distinguish inhibitors of transcription from inhibitors of translation. IC50 determined using an  
E. coli S30 extract either in presence of plasmid pBestluc (n E. coli promoter) or in presence of plasmid pSP-luc+NF (phage SP6 promoter) with added phage 
SP6 RNA polymerase. In experiments using plasmid pBestluc inhibitors of bacterial transcription or translation interfere with the assay, whereas in experiments 
using plasmid pSP-luc+NF only inhibitors of the bacterial translation can interfere. IVTT IC50 [µM] are averages of two independent experiments. . ND: not 
determined. 
In summary, we have developed a convergent and modular strategy for the first total synthesis of mangrolide A (1) in 25 steps (longest 
linear sequence). Salient features of this route include a b-selective glycosylation without neighbouring group assistance to form the 
disaccharide (6 + 14 à 15) and another with the highly congested acceptor alcohol (4 + 17 à 23). We also demonstrated the robustness 
of the macrocycle preparation from three key components, all of which are accessed within 8 steps from commercially available 
starting materials. Evaluation of mangrolide A (1) and its analogues against a panel of pathogenic bacteria revealed no antibiotic 
activity, however, weak inhibition of translation was observed in an in vitro enzyme assay system. The detailed biological study of 
mangrolide A (1) and synthesis of similar 18-membered natural and unnatural antibiotic candidates is ongoing, and will be disclosed 
in due course. 
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